This liver meeting in 2019 is quite interesting for those who are investigating NASH (non-alcoholic steatohepatitis) like me, because you have results regarding makers with interesting mechanism of action like inhibition of non-mainstream drugs that we heard about in previous years so we are seeing new mechanism of action tested with the molecules and phase 2 results which I feel might be interesting, given the field is moving towards the direction of combination. There are also a lot of presentations about biomarkers, non-invasive biomarkers to diagonal slash and the histology of these patients and also to many other treatments which is a very important aspect for the future of when we want to increase the number of patients we treat.
